Kyocera 6-K 2016
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under
the Securities Exchange Act of 1934
For the month of August 2016
Commission File Number: 1-07952
6 Takeda Tobadono-cho, Fushimi-ku,
Kyoto 612-8501, Japan
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Registration S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Registration S-T Rule 101(b)(7): ¨
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
Date: August 26, 2016
Information furnished on this form:
To All Persons Concerned,
Notice Relating to Merger of Kyocera Medical Corporation
Kyocera Corporation (the Company), at a meeting of its Board of Directors held on August 26, 2016, resolved that the Company will merge Kyocera Medical Corporation (Kyocera Medical), a wholly owned consolidated subsidiary of the Company, effective as of April 1, 2017.
The above merger constitutes simplified merger and, accordingly, certain parts of the disclosure are omitted.
Kyocera Medical is Kyocera Groups principal subsidiary in the medical and health care market, one of the Groups important markets. It develops products such as artificial joints, artificial bones and dental implants, taking advantage of the highly biocompatible characteristics of fine ceramics and titanium alloy. The Company believes that expansion of business in this market going forward will increasingly require long-term joint study with research and development institutions and cultivation of new business areas. The purpose of the contemplated merger is to pursue new business opportunities based on the medical materials technologies fostered by Kyocera Medical, and to achieve synergies with the Companys brand and the Companys rich management resources.
In the merger, the Company will be the surviving company, and Kyocera Medical will be dissolved.
The merger is between the Company and a wholly owned subsidiary thereof, and, accordingly, no new shares will be issued and no cash due to merger shall be delivered.
(Millions of Yen)
There will be no change in the trade name, business, location of headquarters, representative directors, capital amount or fiscal year end of the Company as a result of the merger.
Because this merger is between the Company and its wholly owned subsidiary, and the effective date of the merger is scheduled to be April 1, 2017, the merger will have no impact on the financial forecast of the Company for the fiscal year ending March 31, 2017.